|Videos|February 24, 2023
Emerging Biomarkers for Assessing Therapy Response in Colorectal Cancer
The panel discusses other emerging biomarkers for monitoring patient response to therapy for colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than half of patients with microsatellite-stable metastatic colorectal cancer without active liver metastases survived at least 18 months with botensilimab plus balstilimab.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
3
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5